Novo Nordisk A/s

Dr. Reddy's Laboratories, Incorporated

Other

Church Dwight & Co., Inc.

Thyge Borup Hjorth

Helle Weibel

Tina Meinertz Andersen

Lawrence Kirschner

Andrew D Kurtz

Herman L Marder

John J Steinke

Kim Westi Jorgensen

Poul Bertelsen

Nils Gjerlov Hansen

Lars Nygaard

Jo Slashedrgen Svensson

Jorgen Ryhl Svensson

The present invention provides a new stable pharmaceutical composition containing 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiadiazolidine-2,4-dione as active ingredient.

Pharmaceutical composition and the process for its preparation

The present invention provides a new stable pharmaceutical composition containing 5-&lsqb;&lsqb;4-&lsqb;3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl&rsqb;methoxy&rsqb;phenylmethyl&rsqb;thiazolidine-2,4-dione as active ingredient.

Modified release formulations with zero-order drug release containing (R)-1-(3-(10,11-Dihydro-5H-dibenzo&lsqb;a,d&rsqb;cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid, or a pharmaceutically acceptable salt thereof, dispersed in a polymeric matrix having at least one release rate controlling polymer are useful in treating disorders related to both neurogenic inflammation and non-insulin-dependent diabetes mellitus (NIDDM).

Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo&lsqb;a,d&rsqb;cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid

Pharmaceutical composition containing tiagabine hydrochloride and the

Multiparticulate controlled release preparations incorporating an alkalinizing potassium salt, preferably potassium bicarbonate, as an active ingredient, which are suitable for forming pharmaceutical dosage forms for oral administration. Such dosage forms are useful for potassium supplementation and for the treatment of degenerative bone or cardiovascular diseases, e.g., osteoporosis and hypertension.

Alkalinizing potassium salt controlled release preparations

Growing community of inventors

Farum, Denmark

Thyge Borup Hjorth